series-a
Stage
1
Investors
About
Poxel is a French biopharmaceutical company focused on developing innovative therapeutic products for metabolic diseases, including type 2 diabetes and non-alcoholic steatohepatitis (NASH). Their lead product, Twymeeg (Imeglimin), is approved for type 2 diabetes in Japan.
Explore Poxel's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.